CA2812846A1 - Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest - Google Patents

Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest Download PDF

Info

Publication number
CA2812846A1
CA2812846A1 CA2812846A CA2812846A CA2812846A1 CA 2812846 A1 CA2812846 A1 CA 2812846A1 CA 2812846 A CA2812846 A CA 2812846A CA 2812846 A CA2812846 A CA 2812846A CA 2812846 A1 CA2812846 A1 CA 2812846A1
Authority
CA
Canada
Prior art keywords
compound
prostacyclin
treatment
cutoff value
acute traumatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2812846A
Other languages
English (en)
French (fr)
Inventor
Par Johansson
Sisse Rye OSTROWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of CA2812846A1 publication Critical patent/CA2812846A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2812846A 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest Abandoned CA2812846A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070427 2010-10-01
DKPA201070427 2010-10-01
PCT/DK2011/050375 WO2012041334A1 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Publications (1)

Publication Number Publication Date
CA2812846A1 true CA2812846A1 (en) 2012-04-05

Family

ID=44872128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2812846A Abandoned CA2812846A1 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Country Status (9)

Country Link
US (1) US20130261177A1 (cg-RX-API-DMAC7.html)
EP (1) EP2622354A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013543491A (cg-RX-API-DMAC7.html)
KR (1) KR20140025303A (cg-RX-API-DMAC7.html)
CN (2) CN106038570A (cg-RX-API-DMAC7.html)
AU (1) AU2011307494B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013007849A2 (cg-RX-API-DMAC7.html)
CA (1) CA2812846A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012041334A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4330670A4 (en) * 2021-04-28 2025-03-19 Diotex Diagnostics, LLC Methods and devices for quantitatively estimating syndecan-1

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
KR20140053881A (ko) * 2011-04-19 2014-05-08 릭스하스피탈렛 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체
EP2834642A1 (en) * 2012-03-30 2015-02-11 Rigshospitalet Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
WO2015073314A1 (en) 2013-11-13 2015-05-21 Cayman Chemical Company Incorporated Amine salts of a prostacyclin analog
WO2016073668A1 (en) 2014-11-06 2016-05-12 The Regents Of The University Of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN107430136A (zh) * 2015-02-03 2017-12-01 科罗拉多州立大学董事会,公司实体 粘弹性分析用于预测大量出血的用途
DK3278112T3 (da) 2015-03-29 2021-12-13 Endothel Pharma Aps Sammensætning, der omfatter prostacyclin eller analoger deraf, til behandling af akut, kritisk syge patienter
WO2016200765A1 (en) 2015-06-08 2016-12-15 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
US11169142B2 (en) 2016-05-11 2021-11-09 The Regents Of The University Of Colorado, A Body Corporate Viscoelastic analysis in patients with disease associated with cardiovascular system
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
US12440285B2 (en) * 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
CN114113641B (zh) * 2021-10-28 2023-11-03 中科精瓒(武汉)医疗技术有限公司 一种活化凝血检测试剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
AU4405293A (en) * 1992-06-05 1994-01-04 Barbara M. Alving Test for quantitative thrombin time
JPH11322612A (ja) * 1998-03-13 1999-11-24 Toray Ind Inc 肝細胞増殖因子誘引剤
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
EP2063273A1 (en) * 2007-11-21 2009-05-27 Pentapharm GmbH Method for assessing the fibrinogen contribution in coagulation
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
CN102271685A (zh) * 2008-12-30 2011-12-07 斯若姆博洛捷克有限公司 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
ES2477498T3 (es) * 2010-01-20 2014-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4330670A4 (en) * 2021-04-28 2025-03-19 Diotex Diagnostics, LLC Methods and devices for quantitatively estimating syndecan-1

Also Published As

Publication number Publication date
BR112013007849A2 (pt) 2016-06-07
EP2622354A1 (en) 2013-08-07
JP2013543491A (ja) 2013-12-05
WO2012041334A1 (en) 2012-04-05
KR20140025303A (ko) 2014-03-04
CN106038570A (zh) 2016-10-26
CN103238070B (zh) 2016-06-29
AU2011307494A1 (en) 2013-05-02
CN103238070A (zh) 2013-08-07
US20130261177A1 (en) 2013-10-03
AU2011307494B2 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
AU2011307494B2 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
US20150057325A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
ES2670711T3 (es) Receptor soluble del activador de plasminógeno de tipo uroquinasa (suPAR) como marcador de diagnóstico de inflamación de grado bajo
US20160250164A1 (en) Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
Liu et al. Experimental alcoholism primes structural and functional impairment of the glymphatic pathway
JP2014514310A (ja) 毛細血管漏出の予防及び治療のために手術時に投与されるプロスタサイクリン及びその類似体
Wożakowska-Kapłon et al. Oral health status and the occurrence and clinical course of myocardial infarction in hospital phase: A case-control study
Yagi et al. Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats
US20230314448A1 (en) Methods of treating patients at risk for renal injury and renal failure
ES2898424T3 (es) Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
Warden Fluid resuscitation and early management
Taguchi et al. Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway
Weber et al. Time course of systemic and renal plasma prostanoid concentrations and renal function in ovine hyperdynamic sepsis
WO2018166813A1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
Hinkelbein et al. Local cerebral blood flow is preserved in sepsis
Gallieni et al. Impaired brachial artery endothelial flow-mediated dilation and orthostatic stress in hemodialysis patients
Connelly et al. The SGLT2i Dapagliflozin Reduces RV Hypertrophy Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding
WO2024083820A1 (en) Method and composition for determining the level of o-glcnacylation in horses
WO2010149172A2 (en) SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
Sahin et al. Clinical Investigations Relationship Between Endothelial Functions
AV Comparison of Antihypertensive Efficacy and Perinatal Safety of Labetalol and Methyldopa in the Treatment of Hypertension in Pregnancy
TW201134484A (en) Therapeutic use
Kathrin et al. Early recognition and

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160909

FZDE Discontinued

Effective date: 20181002